Cytomedix Inc.
Description Cytomedix, Inc. develops, sells, and licenses regenerative biological therapies to primarily address the areas of wound care, infection control, and orthopedic surgery. The company offers The AutoloGel System, a point of care device for the production of a platelet based bioactive therapy derived from the patients own blood; and Angel cPRP System for producing platelet rich plasma and platelet poor plasma from whole blood or bone marrow. Its Angel product line also includes ancillary products, such as phlebotomy and applicator supplies; and activAT, which produces autologous thrombin serum from platelet poor plasma. The companys product pipeline includes ALD-401, an autologous preparation of bright cells, which completed the initial safety stage of the study for the post-acute treatment of ischemic stroke; ALD-451, an autologous preparation of bright cells, which is in Phase I clinical study for treating brain cancer; and ALD-301, which is in clinical development stage for treating peripheral arterial disease. It sells its products through direct sales representatives and independent sales agents in the United States, as well as through a network of distributors in Europe, the Middle East, Canada, and Australia. The company was formerly known as Autologous Wound Therapy, Inc. and changed its name to Cytomedix, Inc. in 2000. Cytomedix, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland. To view the detailed information, you need to SUBSCRIBE with us. |
 |